This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

emtricitabine/tenofovir disoproxil unspecified

Reference No. 4623

Publication date:

Appraisal information

emtricitabine/tenofovir disoproxil unspecified 200 mg/245 mg film-coated tablet

Company: Not specified
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Not applicable
Status: Recommended
Advice No: 0420
Ratification by Welsh Government: 30/06/2020

Current Progress

Ratification by
Welsh Government

AWMSG advice

Emtricitabine/tenofovir disoproxil is recommended for use within NHS Wales in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. Adults at high risk include the following populations: • men who have sex with other men (MSM) and transgender people having sex with men who are engaging in condomless anal sex. • heterosexual and same-sex, HIV-1 negative partners who are in relationships with HIV-1 positive partners whose viral replication is not suppressed. • other heterosexuals considered to be at high risk. Emtricitabine/tenofovir disoproxil should be prescribed on the basis of lowest acquisition cost.